Clopidogrel
Product Images NDC 67296-2060

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 67296-2060). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal bar chart titled 'Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel 75 mg Alone or with Proton Pump Inhibitors (PPIs).' It compares the effect of four PPIs (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg) on the active metabolite AUC of Clopidogrel. The x-axis shows change relative to clopidogrel administered alone, ranging from 0.4 to 1.4, with mean values and 90% confidence intervals plotted for each PPI.*

FDA Label Image

Package Label-principal Display Panel (75 mg Blister Carton (10 x 10 Unit-dose))

Packaging label for Clopidogrel Tablets, USP 75 mg, showing a box containing 100 unit-dose tablets (10 x 10). The label includes the brand name Clopidogrel with strength 75 mg prominently displayed, the manufacturer Aurobindo Pharma USA, Inc., and instructions to pharmacists to dispense the Medication Guide separately. The label also shows an NDC number 65862-357-10 and mentions the tablets are film-coated containing 97.875 mg of clopidogrel bisulfate equivalent to 75 mg clopidogrel base.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph showing cumulative event rate percentages over 12 months of follow-up for cardiovascular death, myocardial infarction, and stroke. It compares two groups: placebo (+ aspirin) and clopidogrel (+ aspirin), with clopidogrel showing a lower cumulative event rate. A p-value of 0.00009 is noted, indicating statistical significance.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

This forest plot chart compares hazard ratios with 95% confidence intervals for various subgroups including age, gender, race, comorbidities, and concurrent medications, between Clopidogrel and placebo groups in a study with 12,562 participants. The horizontal axis ranges from 0.3 to 1.4, indicating the relative risk favoring either Clopidogrel or placebo across the subgroups.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A line graph comparing the percentage of deaths before first discharge over 28 days between patients treated with Clopidogrel and those given a placebo. The x-axis represents days since randomization (up to 28), and the y-axis shows the percent dead before discharge. The graph indicates 7.5% deaths (1726 deaths) for Clopidogrel and 8.1% deaths (1845 deaths) for placebo, with a noted 7% proportional risk reduction (p = 0.03) for Clopidogrel.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A Kaplan-Meier curve comparing the percentage of patients with death, reinfarction, or stroke before first discharge between Clopidogrel and placebo groups. The x-axis shows days since randomization (up to 28 days), and the y-axis shows the percentage of patients with these events. The graph illustrates a 9% proportional risk reduction with Clopidogrel compared to placebo.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot chart showing odds ratios with 99% confidence intervals comparing the effect of Clopidogrel versus placebo across various subgroups based on gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The plot indicates which subgroups favor Clopidogrel or placebo, with a vertical line at an odds ratio of 1 as the reference.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph depicting the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up. Two lines represent treatment groups: one for Aspirin and one for Clopidogrel. The y-axis shows cumulative event rate up to 16%, and the x-axis shows months of follow-up from 0 to 36. The graph indicates lower event rates for Clopidogrel compared to Aspirin, with a p-value of 0.045 shown on the image.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A forest plot chart comparing hazard ratios with 95% confidence intervals for qualifying conditions including Stroke, MI (Myocardial Infarction), and PAD (Peripheral Artery Disease) between Clopidogrel and Aspirin groups, including overall data. The x-axis represents hazard ratios ranging approximately from 0.6 to 1.3, indicating relative risk favoring either Clopidogrel or Aspirin.*

FDA Label Image

Package Label-principal Display Panel (75 mg (30 Tablets Bottle))

Label for Clopidogrel Tablets USP 75 mg, containing 30 film-coated tablets. The label displays dosage strength, storage instructions, and distributor information for Aurobindo Pharma USA, Inc. It also notes the medication is Rx only and made in India. The packaging emphasizes pharmacist dispensing and includes a barcode.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure diagram of Clopidogrel, showing its molecular arrangement including a thiophene ring, ester group, chlorophenyl moiety, and sulfate (H2SO4) salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.